Please login to the form below
Exondys 51
This page shows the latest Exondys 51 news and features for those working in and with pharma, biotech and healthcare.
Sarepta rival NS Pharma files Duchenne drug with FDA
The treatment is a follow-up to Sarpeta’s Exondys 51, the first and currently only disease-modifying treatment approved in the US for the inherited muscle-wasting disease. ... Vyondys uses the same ‘exon skipping’ mechanism, but helps patients with
Latest news
-
FDA rejects Sarepta’s new Duchenne drug over safety fears
Vyondys 53 (golodirsen) follows Exondys 51, the first and currently only disease-modifying treatment approved in the US for the inherited muscle-wasting disease. ... Sarepta gained approval for Exondys 51 three years ago amid controversy about its lack
-
FDA will maintain the pace, vows Woodcock, but warns of skills gap
These cases have, of course, not been without controversy – one of the most notable being the approval of Sarepta’s Duchenne treatment Exondys 51 in 2016, despite questionable data.
-
Duchenne UK backs Evox dystrophin delivery project
At the moment that includes already-market drugs that skip over or ignore the mutation in the dystrophin gene – such as PTC Therapeutics’ Translarna (ataluren) and Sarepta’s Exondys 51 (eteplirsen) –
-
CHMP backs Spark’s Luxturna, but rejects Sarepta again
Eteplirsen was approved in the US as Exondys 51 in 2016, although the decision came after FDA reviewers recommended that the drug be rejected as the evidence for its benefits was ... which there was no meaningful difference between Exondys and placebo in
-
Pfizer abandons antibody for Duchenne
News of the setback spurred modest gains in the share price of Sarepta, which sells exon-skipping therapy Exondys 51 (eteplirsen) in the US and Europe, as well as PTC Therapeutics
More from news
Approximately 3 fully matching, plus 13 partially matching documents found.
Latest Intelligence
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Alnylam can take heart in exceptions, however, such as Sarepta, with its Duchenne treatment Exondys 51, and hope it too can buck this trend.
-
Europe vs the US: New drug product approvals
Among the noteworthy orphan approvals are Exondys 51 (for the treatment of Duchenne muscular dystrophy, only approved in the US), Darzalex (for the treatment of multiple myeloma, approved in the US
-
Deal Watch February 2017
Licence. 145. Sarepta Therapeutics/ Gilead Sciences. PRV received when EXONDYS 51 was FDA approved for Duchenne muscular dystrophy.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Featured jobs
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
-
Account Director
-
Salary TBC
- Senior Editor - Medical Communications - South East - Buckingham...
-
Highly competitive salary &package
-
Account Executive
-
Salary TBC
- Scientific Director - Medical Communications - Berkshire
-
Excellent package on offer
-
Account Supervisor
-
Salary TBC
-
Account Director, Medical Education
-
Salary TBC
- Entry Level Editorial Assistant – Medical Education –Buckinghams...
-
Highly Competitive
-
Senior Medical Writer
-
Salary TBC
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
Subscribe to our email news alerts
- The first of many celebrations for Lucid Group at Middlesex House
- FDA advisors say no to empagliflozin in type 1 diabetes
- Roche’s Spinraza, Zolgensma rival risdiplam hits the mark in SMA
- MSD hangs ‘for sale’ sign on French facility, shedding 207 staff
- Novartis makes case for NASH candidate tropifexor
- Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day
- RWE Blog 3: Is real-world evidence the holy grail
- What do Healthcare Professionals think about the inclusion of remote selling techniques?
- Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day
- BeiGene bags FDA approval for first product Brukinsa in lymphoma
- Amarin wins FDA advisory nod for Vascepa cardiovascular expansion
- Shionogi scores FDA approval for new cUTI antibiotic
PMHub
COUCH Health
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...
Latest intelligence
- RWE Blog 3: Is real-world evidence the holy grail
- We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
- What do Healthcare Professionals think about the inclusion of remote selling techniques?
- Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
- Strengthening business competition and reducing anti-competitive practices
- How the CMA is tackling high prices for essential drugs...
Quick links
Infographics
